D. Morgensztern

G. Colditz, S. Broderick, T. Crabtree, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

G. Colditz, S. Broderick, T. Crabtree, 2016, The Journal of thoracic and cardiovascular surgery.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

L. Schwartz, R. Govindan, J. Neal, 2022, Journal for ImmunoTherapy of Cancer.

The role of surgery in stage IIIA non-small cell lung cancer: a decision and cost-effectiveness analysis

G. Colditz, T. Crabtree, V. Puri, 2014 .

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Alex H. Wagner, Zachary L. Skidmore, R. Wilson, 2018, Nature Communications.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer

J. Subramanian, R. Govindan, K. Trinkaus, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer

R. Herbst, K. Shibuya, D. Morgensztern, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution.

R. Govindan, B. Goodgame, D. Morgensztern, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database

I. Lossos, D. Morgensztern, A. Stefanovic, 2008, Leukemia & lymphoma.

KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.

D. Morgensztern, 2019, Journal of thoracic disease.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer.

David R. Jones, T. Crabtree, D. Kreisel, 2017, The Annals of thoracic surgery.

IsThere a Role for Cetuximab in Non ^ Small Cell Lung Cancer?

R. Govindan, D. Morgensztern, 2007 .

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

M. Socinski, N. Reinmuth, C. Gridelli, 2020, Clinical lung cancer.

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

C. Rudin, R. Govindan, R. Salgia, 2015 .

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

M. Socinski, C. Gridelli, Michael Thomas, 2021, Frontiers in Oncology.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A. Drilon, M. Ahn, A. Wozniak, 2018, Cancer discovery.

Barriers for accrual to clinical trials in adult patients (pts) with thoracic malignancies.

R. Govindan, D. Morgensztern, M. Baggstrom, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary plasma cell leukemia

Jingqin Luo, R. Vij, D. Morgensztern, 2009, Cancer.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Immune checkpoint inhibition in patients with brain metastases.

D. Morgensztern, T. Johanns, S. Waqar, 2016, Annals of translational medicine.

Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.

R. Govindan, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of immune checkpoint blockers in patients with EGFR mutation.

D. Morgensztern, J. Ward, 2018, Translational lung cancer research.

Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer

Y. Shentu, B. Cho, N. Reguart, 2022, Clinical lung cancer.

Immunogenicity of Influenza Vaccination in Patients With Cancer

F. Gao, R. Govindan, D. Morgensztern, 2015, American journal of clinical oncology.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors.

F. Gao, R. Govindan, D. Morgensztern, 2022, Lung cancer.

Radiation Recall Dermatitis Induced by Methotrexate in a Patient With Hodgkin’s Disease

A. Markoe, D. Morgensztern, L. Bartlett-Pandite, 2000, American journal of clinical oncology.

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

C. Rudin, R. Govindan, D. Carbone, 2018, Pneumologie.

A roundup of recently published articles relevant to thoracic oncology.

R. Govindan, D. Morgensztern, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic factors influencing survival in solitary plasmacytoma

R. Vij, D. Morgensztern, G. Ramsingh, 2009, British journal of haematology.

Lorlatinib: a new-generation drug for ALK-positive NSCLC.

D. Morgensztern, S. Waqar, 2018, The Lancet. Oncology.

Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.

I. Lossos, D. Morgensztern, G. Walker, 2007 .

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

R. Heist, K. Kelly, E. Vokes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Precision medicine in lung cancer: the battle continues.

D. Morgensztern, S. Waqar, 2016, Journal of thoracic disease.

A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021 .

US breast cancer mortality trends in young women according to race

M. Ellis, R. Aft, Cynthia X Ma, 2015, Cancer.

Warm-Antibody Autoimmune Hemolytic Anemia Developing after Thrombotic Thrombocytopenic Purpura

D. Morgensztern, M. Kharfan-Dabaja, H. Tsai, 2002, Acta Haematologica.

Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia

D. Morgensztern, L. Raez, P. Cassileth, 2005, Leukemia & lymphoma.

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.

R. Govindan, Keunchil Park, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

P. Paik, E. Felip, D. Morgensztern, 2019, Lung cancer.

Central nervous system toxicities of chemotherapeutic agents

D. Morgensztern, Srinivas Peddi, Parvin F. Peddi, 2014, Expert review of anticancer therapy.

Central nervous system toxicities of chemotherapeutic

D. Morgensztern, Srinivas Peddi, Parvin F. Peddi, 2014 .

Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis

I. Lossos, L. Koniaris, D. Morgensztern, 2011, Leukemia & lymphoma.

Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature

D. Morgensztern, L. Raez, E. Santos, 2003, American Journal of Gastroenterology.

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

B. V. Van Tine, D. Morgensztern, D. Adkins, 2014, Cancer medicine.

Genomic alterations in lung adenocarcinoma.

R. Govindan, D. Morgensztern, Ramaswamy Govindan, 2015, The Lancet. Oncology.

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

C. Rudin, R. Govindan, D. Carbone, 2019, Clinical Cancer Research.

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2016 .

Mutational Events in Lung Cancer: Present and Developing Technologies

C. Maher, R. Govindan, T. Mitsudomi, 2018 .

Immunotherapy in Lung Cancer.

R. Herbst, D. Morgensztern, L. Du, 2017, Hematology/oncology clinics of North America.

Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer

R. Herbst, D. Morgensztern, 2016, Clinical Cancer Research.

Second-line therapy for esophageal cancer

R. Govindan, D. Morgensztern, Mike G Martin, 2007, Expert review of anticancer therapy.

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

R. Govindan, K. Pepin, D. Morgensztern, 2022, Frontiers in Oncology.

Genomic Profiling of Lung Adenocarcinoma in Never-Smokers

R. Wilson, R. Fulton, L. Ding, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

R. Heist, K. Kelly, E. Vokes, 2021, Clinical Cancer Research.

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

R. Govindan, R. Suresh, D. Morgensztern, 2021, Journal of thoracic disease.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical next‐generation sequencing in patients with non–small cell lung cancer

Rakesh Nagarajan, John D Pfeifer, Shashikant Kulkarni, 2015, Cancer.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

Immune Checkpoint Inhibition in Lung Cancer

R. Herbst, D. Morgensztern, 2018 .

Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.

R. Govindan, D. Morgensztern, S. Devarakonda, 2013, Oncology.

Molecularly targeted therapies in locally advanced non-small-cell lung cancer.

R. Govindan, D. Morgensztern, S. Devarakonda, 2013, Clinical lung cancer.

Trends in Stage I Lung Cancer.

F. Gao, R. Govindan, V. Puri, 2022, Clinical lung cancer.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Jeffrey Bradley, Feng Gao, R. Govindan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

C. Rudin, R. Govindan, A. Chaudhuri, 2019, Clinical Cancer Research.

Gene expression profiling in diffuse large B-cell lymphoma

I. Lossos, D. Morgensztern, Mike G Martin, 2007, Leukemia & lymphoma.

Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

G. Colditz, R. Govindan, J. Bradley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC

T. Burns, P. Ward, D. Camidge, 2021 .

A roundup of articles published in recent months.

J. Subramanian, R. Govindan, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Best of the month: a roundup of articles published in recent months.

R. Govindan, D. Morgensztern, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel cytotoxic agents.

D. Morgensztern, C. Belani, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

R. Govindan, D. Morgensztern, S. Waqar, 2016, Chemotherapy.

Targeted Therapy in Solid Tumors: Lung Cancer

R. Herbst, D. Morgensztern, S. Waqar, 2015 .

Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.

J. Subramanian, R. Govindan, D. Morgensztern, 2011, Clinical lung cancer.

Chemotherapy for Advanced-Stage Non–Small Cell Lung Cancer

D. Morgensztern, L. Du, 2015, Cancer journal.

Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005

J. Subramanian, R. Govindan, D. Morgensztern, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

F. Gao, C. Liang, L. Ratner, 2022, Cancer Chemotherapy and Pharmacology.

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

R. Heist, K. Kelly, E. Vokes, 2021, JTO clinical and research reports.

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

R. Govindan, Keunchil Park, S. Peters, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

R. Govindan, B. V. Van Tine, A. Lockhart, 2020, Cancer Chemotherapy and Pharmacology.

Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy

M. Socinski, P. Postmus, D. Morgensztern, 2019, Cancer.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

J. Trepel, P. Ma, D. Morgensztern, 2019, British Journal of Cancer.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

R. Govindan, G. Fasola, P. Postmus, 2018, Cancer.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting.

R. Govindan, D. Morgensztern, 2014, Clinical lung cancer.

Epidermal Growth Factor Receptor , Human Epidermal Growth Factor Receptor 2 , and Human Epidermal Growth Factor Receptor 3

R. Govindan, D. Morgensztern, 2013 .

EGFRMutations in Non – Small-Cell Lung Cancer Find , Divide , and Conquer

R. Herbst, K. Politi, D. Morgensztern, 2015 .

Management of patients with advanced non-small cell lung cancer: role of gefitinib

R. Govindan, V. Velcheti, D. Morgensztern, 2010, Biologics : targets & therapy.

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.

R. Govindan, D. Morgensztern, T. Fong, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Liquid Biopsies: New Technology and Evidence

D. Morgensztern, 2021, Lung Cancer.

Systemic Treatment of Brain Metastases.

R. Govindan, D. Morgensztern, S. Waqar, 2017, Hematology/oncology clinics of North America.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Roy S Herbst, R. Herbst, K. Politi, 2015, JAMA oncology.

Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011

J. Subramanian, R. Govindan, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of Next-Generation Sequencing Technologies

R. Govindan, D. Morgensztern, S. Devarakonda, 2013 .

Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant

D. Morgensztern, H. Fernandez, E. Santos, 2003, Bone Marrow Transplantation.

Prevalence of Hepatitis C Infection in Patients with Non-Hodgkin's Lymphoma in South Florida and Review of the Literature

I. Lossos, K. Hamilton-Nelson, D. Morgensztern, 2004, Leukemia & lymphoma.

Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study).

R. Herbst, D. Morgensztern, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed nausea and vomiting from carboplatin doublet chemotherapy

R. Govindan, D. Morgensztern, S. Waqar, 2016, Acta oncologica.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

B. Loo, R. Heist, J. Hayman, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Miscellaneous agents.

R. Herbst, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic lymphocytic leukemia‐associated nephrotic syndrome caused by focal segmental glomerulosclerosis

I. Lossos, D. Morgensztern, P. Ruiz, 2004, American journal of hematology.

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Marilyn M. Li, T. Burns, S. Ramalingam, 2019, Lung cancer.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

R. Govindan, D. Morgensztern, F. Gao, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature

I. Lossos, D. Morgensztern, M. Rosado, 2005, Leukemia & lymphoma.

Somatostatin Receptor Scintigraphy in MALT Lymphoma of the Lacrimal Gland Treated with Rituximab

I. Lossos, D. Morgensztern, A. Serafini, 2004, Leukemia & lymphoma.

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non–Small Cell Lung Cancer

R. Govindan, V. Puri, D. Morgensztern, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multimodality Therapy for NSCLC.

D. Morgensztern, S. Waqar, L. Du, 2016, Cancer treatment and research.

Non–small‐cell Lung Cancer With Brain Metastasis at Presentation

R. Govindan, J. Bradley, V. Puri, 2018, Clinical lung cancer.

Abstract A52: Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI)

R. Govindan, D. Morgensztern, Jennifer C. King, 2020 .

Primary Non-Hodgkin’s Lymphoma of the Lung.

I. Lossos, D. Morgensztern, T. Fong, 2007 .

Squamous cell cancer of the head and neck with distant metastasis at presentation

K. Trinkaus, D. Morgensztern, D. Adkins, 2011, Head & neck.

Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474

R. Govindan, D. Morgensztern, 2006, Expert review of anticancer therapy.

Molecular prognostic factors in diffuse large B-cell lymphoma

I. Lossos, D. Morgensztern, 2005, Current treatment options in oncology.

Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis

J. Subramanian, R. Govindan, J. Piccirillo, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website

J. Subramanian, R. Govindan, D. Morgensztern, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vaccines and Immunotherapy for Non-small Cell Lung Cancer

R. Govindan, B. Goodgame, D. Morgensztern, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials

R. Govindan, D. Morgensztern, S. Waqar, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer

J. Subramanian, R. Govindan, D. Morgensztern, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.

C. Rudin, Melissa L. Johnson, D. Brickman, 2020, Lung cancer.

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

R. Heist, K. Kelly, E. Vokes, 2019, Journal of Clinical Oncology.

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.

E. Felip, T. Owonikoko, D. Morgensztern, 2022, Future oncology.

Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014

R. Govindan, D. Morgensztern, M. Amin, 2020, BMC Endocrine Disorders.

Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma

I. Lossos, A. Alencar, D. Morgensztern, 2007, Leukemia & lymphoma.

1359TiP RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study

D. Morgensztern, N. Iannotti, A. Chaudhry, 2021, Annals of Oncology.

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer

G. Colditz, J. Bradley, T. Crabtree, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.

T. Choueiri, L. Smith, A. Patnaik, 2021 .

Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base.

D. Boffa, F. Detterbeck, Zuoheng Wang, 2014, The Annals of thoracic surgery.

Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis

J. Subramanian, R. Govindan, B. Goodgame, 2008 .

The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer

R. Govindan, B. Goodgame, D. Morgensztern, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003

Kathryn Trinkaus, Janakiraman Subramanian, Feng Gao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer.

R. Govindan, D. Morgensztern, S. Devarakonda, 2020, Cancer cell.

Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

R. Govindan, R. Herbst, J. Schiller, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

G. Colditz, T. Crabtree, D. Kreisel, 2015, The Annals of thoracic surgery.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?

D. Morgensztern, S. Waqar, 2015, Expert review of clinical immunology.

Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer.

R. Govindan, J. Bradley, D. Morgensztern, 2022, International journal of radiation oncology, biology, physics.

A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer

R. Govindan, D. Morgensztern, M. Perry, 2008, Acta oncologica.

FP07.13 Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer

R. Govindan, D. Morgensztern, J. Ward, 2021 .

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

E. Felip, T. Owonikoko, D. Morgensztern, 2021, Journal of Clinical Oncology.

ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

C. Rudin, R. Govindan, L. Byers, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced NSCLC: Finding the right prescription for oncologist education.

J. C. Williamson, R. Govindan, D. Morgensztern, 2014 .

Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.

R. Govindan, D. Morgensztern, R. Lanman, 2016 .

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.

S. Broderick, T. Crabtree, D. Kreisel, 2017, The Annals of thoracic surgery.

Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer

D. Morgensztern, J. Jennings, A. Tomasian, 2017, CardioVascular and Interventional Radiology.

High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnos

I. Lossos, D. Morgensztern, P. Hosein, 2010, Leukemia & lymphoma.

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

J. Berlin, A. Tolcher, P. Janne, 2023, Journal of Clinical Oncology.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Edward S. Kim, M. Socinski, C. Gridelli, 2017, Lung Cancer.

Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.

C. Gross, G. Michaud, L. Tanoue, 2013, Chest.

Abstract P4-14-04: United States breast cancer mortality trends in young women according to race

R. Aft, F. Ademuyiwa, D. Morgensztern, 2015 .

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

B. Cho, N. Reguart, D. Morgensztern, 2021 .

MET Mutation Associated with Responsiveness to Crizotinib.

D. Morgensztern, S. Waqar, Jennifer K Sehn, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

J. Subramanian, R. Govindan, D. Morgensztern, 2005 .

Survival for nasopharyngeal cancer with distant metastatic disease at presentation.

Q. Zhang, D. Morgensztern, D. Adkins, 2016, Journal of Clinical Oncology.

First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

B. Rini, R. Kelley, A. El-Khoueiry, 2022, Journal of Clinical Oncology.

Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.

T. Burns, P. Ward, D. Camidge, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T

I. Lossos, D. Morgensztern, P. Hosein, 2008 .

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

G. Colditz, S. Broderick, T. Crabtree, 2015, The Annals of thoracic surgery.

Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database.

D. Boffa, F. Detterbeck, R. Decker, 2013, The Journal of surgical research.

Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer

C. Gross, L. Tanoue, F. Detterbeck, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer

M. Watson, R. Govindan, K. Trinkaus, 2015, American journal of clinical oncology.

Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.

R. Govindan, D. Morgensztern, 2008, Clinical lung cancer.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

B. Loo, R. Heist, J. Hayman, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Somatic mutations in mismatch repair pathway genes in non-small cell lung cancer.

R. Govindan, D. Morgensztern, L. Maggi, 2016 .

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .

Characteristics of 1q amplification in adenocarcinoma of the lung (LUAD).

B. Ozenberger, R. Govindan, D. Morgensztern, 2014 .